Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases

NCT04375748 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 756

Last updated 2023-07-24

No results posted yet for this study

Summary

To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.

Conditions

  • Acute Myocarditis

Interventions

DIAGNOSTIC_TEST

Performing routine care (clinical and paraclinical tests)

ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI

DIAGNOSTIC_TEST

Examinations for the research:

Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis. A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Clément Delmas · CHU Toulouse, Hôpital Rangueil

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-12-28
Completion
2021-12-28

Countries

  • France
  • Martinique
  • Mayotte
  • Reunion

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04375748 on ClinicalTrials.gov